Who is sponsoring NCT05006911?

NCT05006911 is sponsored by Optall Vision.

What condition does NCT05006911 study?

NCT05006911 studies Presbyopia.

Is NCT05006911 still recruiting?

NCT05006911 is currently status unknown. Last updated 17 August 2021.

Last reviewed 2021-08-17 · How we verify

NCT05006911: PBO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

Status unknown Phase 1 Last updated 17 August 2021

What this trial tests

Phase 1 trial testing Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound in Presbyopia in 11 participants. Status unknown.

Timeline

14 August 2021

Primary endpoint
1 September 2021

15 September 2021

Quick facts

Lead sponsor	Optall Vision
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	14 August 2021
Primary completion	1 September 2021
Estimated completion	15 September 2021
Sites	1 location across Mexico

Drugs / interventions tested

Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound — full drug profile →

Conditions studied

Presbyopia — all drugs for Presbyopia →

Sponsor

Optall Vision — full company profile →

Who can join

Adults 40 to 60, any sex, with Presbyopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological Treatment in Presbyopia.
Grzybowski A, Ruamviboonsuk V. · · 2022 · cited 27× · PMID 35268476 · DOI 10.3390/jcm11051385

Verify or expand the search:

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
NCT07113210 — Quality of Life in Presbyopic Patients Who Are Treated With Qlosi · Phase 4 · recruiting
NCT06948357 — Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients · Phase 2 · recruiting

Other Optall Vision trials

Trials by the same sponsor.

NCT05001243 — Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients · Phase 1 · unknown
NCT05006898 — Compound to Control Presbyopia Symptoms · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05006911 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Optall Vision
Last refreshed: 17 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05006911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing